Stock 300347 HANGZHOU TIGERMED CONSULTING CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
59.11 CNY -0.94% Intraday chart for Hangzhou Tigermed Consulting Co., Ltd +18.86% +7.53%
Apr. 25 Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 MT
Apr. 25 Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 47,335 139,718 104,196 87,567 44,807 47,911 - -
Enterprise Value (EV) 1 46,226 129,700 96,434 82,021 40,354 42,873 37,504 37,122
P/E ratio 55.9 x 73.8 x 38.7 x 45 x 23.5 x 29.4 x 20 x 18.2 x
Yield 0.44% 0.19% 0.39% 0.52% 1.03% 0.77% 1.07% 1.02%
Capitalization / Revenue 16.9 x 43.8 x 20 x 12.4 x 6.07 x 5.85 x 4.83 x 4.2 x
EV / Revenue 16.5 x 40.6 x 18.5 x 11.6 x 5.47 x 5.23 x 3.78 x 3.25 x
EV / EBITDA 40.8 x 56.2 x 25.2 x 27.7 x 13.7 x 15.2 x 11.1 x 9.42 x
EV / FCF 108 x 154 x 91.3 x 90 x 47.9 x 23 x 16.5 x 16.8 x
FCF Yield 0.93% 0.65% 1.1% 1.11% 2.09% 4.34% 6.07% 5.97%
Price to Book 11.2 x 8.75 x 6.15 x 4.67 x 2.28 x 2.31 x 2.01 x 1.83 x
Nbr of stocks (in thousands) 749,557 872,509 860,729 864,949 866,366 864,949 - -
Reference price 2 63.15 161.6 127.8 104.8 54.97 59.11 59.11 59.11
Announcement Date 2/28/20 3/29/21 3/10/22 3/28/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,803 3,192 5,214 7,085 7,384 8,197 9,919 11,408
EBITDA 1 1,132 2,308 3,820 2,963 2,949 2,821 3,368 3,942
EBIT 1 1,085 2,222 3,697 2,678 2,610 2,798 3,338 3,835
Operating Margin 38.69% 69.62% 70.91% 37.8% 35.35% 34.13% 33.65% 33.62%
Earnings before Tax (EBT) 1 1,089 2,219 3,690 2,595 2,490 2,583 3,192 3,537
Net income 1 841.6 1,750 2,879 2,016 2,027 2,034 2,583 2,868
Net margin 30.02% 54.81% 55.22% 28.45% 27.44% 24.81% 26.04% 25.14%
EPS 2 1.130 2.190 3.300 2.330 2.340 2.014 2.949 3.241
Free Cash Flow 1 428 842.9 1,057 910.9 842 1,862 2,276 2,215
FCF margin 15.27% 26.4% 20.27% 12.86% 11.4% 22.72% 22.94% 19.42%
FCF Conversion (EBITDA) 37.81% 36.52% 27.66% 30.74% 28.55% 66.01% 67.56% 56.2%
FCF Conversion (Net income) 50.85% 48.17% 36.7% 45.18% 41.55% 91.55% 88.11% 77.24%
Dividend per Share 2 0.2780 0.3000 0.5000 0.5500 0.5680 0.4534 0.6302 0.6032
Announcement Date 2/28/20 3/29/21 3/10/22 3/28/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,819 1,818 1,776 3,594 1,812 1,679 1,805 1,906 3,711 1,940 1,734 1,660 2,124 2,254 2,165 - -
EBITDA - - - - - - - - - - - - - - - - -
EBIT 1,356 654.4 826.5 906.4 520.1 581.4 418.2 480.8 1,599 713.1 - - - - - - -
Operating Margin 74.57% 36% 46.53% 25.22% 28.71% 34.62% 23.18% 25.22% 43.08% 36.77% - - - - - - -
Earnings before Tax (EBT) 1 1,349 656 823.9 1,480 526.1 588.9 631.1 968.1 1,599 715.3 175.7 - 526 711.1 683.2 - -
Net income 1 1,093 518.4 673.6 1,192 412.7 411.4 568.5 819.9 1,388 491.3 146.9 - 409.3 554.3 532.6 - -
Net margin 60.11% 28.52% 37.92% 33.16% 22.78% 24.5% 31.5% 43.01% 37.41% 25.33% 8.47% - 19.28% 24.6% 24.6% - -
EPS 2 1.260 0.6000 0.7800 - 0.4800 0.4700 0.6600 0.9500 - 0.5600 0.1700 0.2700 0.4896 0.5827 0.6452 0.6600 0.6800
Dividend per Share 2 0.5000 - - - - 0.5500 - - - - 0.5680 - - - 0.3969 - -
Announcement Date 3/10/22 4/26/22 8/25/22 8/25/22 10/25/22 3/28/23 4/25/23 8/25/23 8/25/23 10/27/23 3/28/24 4/25/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,109 10,018 7,762 5,546 4,452 5,038 9,363 9,888
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 428 843 1,057 911 842 1,862 2,276 2,215
ROE (net income / shareholders' equity) 23.7% 18.7% 16.8% 10.7% 9.95% 8.6% 10.1% 10.4%
ROA (Net income/ Total Assets) 14.3% 12.9% 13.3% 7.84% 7.09% 6.93% 7.54% 5.2%
Assets 1 5,906 13,519 21,624 25,715 28,564 29,345 34,240 55,117
Book Value Per Share 2 5.640 18.50 20.80 22.40 24.10 25.60 29.40 32.30
Cash Flow per Share 2 0.7000 1.140 1.630 1.560 1.320 2.330 2.510 2.820
Capex 1 99.5 156 367 447 308 396 376 460
Capex / Sales 3.55% 4.88% 7.04% 6.3% 4.18% 4.83% 3.8% 4.03%
Announcement Date 2/28/20 3/29/21 3/10/22 3/28/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hangzhou Tigermed Consulting Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
59.11 CNY
Average target price
73.04 CNY
Spread / Average Target
+23.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HANGZHOU TIGERMED CONSULTING CO., LTD Stock Hangzhou Tigermed Consulting Co., Ltd
+7.53% 6.6B
MODERNA, INC. Stock Moderna, Inc.
+22.56% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.34% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.20% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.83% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.71% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.11% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 300347 Stock
  4. Financials Hangzhou Tigermed Consulting Co., Ltd